The EEF1D Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung adenocarcinoma cell line NCI-H1975. This product features targeted disruption of the EEF1D gene, which encodes the elongation factor 1 delta subunit of the eukaryotic elongation factor 1 (eEF1) complex. The polyclonal format provides a heterogeneous pool of knockout cells, enabling robust loss-of-function studies without requiring single-cell cloning. This population is ideal for investigating the functional consequences of EEF1D ablation in a disease-relevant context.
The NCI-H1975 parental line is a widely used model of EGFR-mutant non-small cell lung cancer (NSCLC), originating from a lung adenocarcinoma patient. These cells harbor endogenous activating EGFR L858R/T790M mutations, conferring sensitivity to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs), as well as a PIK3CA mutation that co-activates PI3K/AKT signaling. As a result, NCI-H1975 cells serve as a clinically relevant platform for studying TKI resistance mechanisms and translational control in oncogenic signaling networks.
EEF1D encodes the delta subunit of the eEF1 complex, which mediates GTP-dependent delivery of aminoacyl-tRNAs to the ribosome during the elongation phase of mRNA translation. This subunit interacts directly with eEF1A, eEF1B alpha, eEF1B gamma, valyl-tRNA synthetase, and the zinc finger protein ZPR1, forming a multi-functional hub that couples protein synthesis to cellular homeostasis. Upstream signaling from activated EGFR and the MAPK/ERK cascade, including ERK1/2 and PKC, regulates EEF1D activity and complex assembly. Downstream, EEF1D influences global translation rates, cell proliferation signals, and actin cytoskeleton organization, thereby linking growth factor signaling to the translational machinery.
Disruption of EEF1D in NCI-H1975 cells is expected to impair the eEF1 complex function, leading to attenuated protein synthesis that may compromise the rapid proliferation characteristic of EGFR-driven cancer cells. In particular, the knockout can be used to probe how loss of translation elongation factors affects ERK pathway output and the cellular response to TKI treatment. Given the interaction between eEF1D and actin dynamics, this model also permits investigation of cytoskeletal reorganization in invasive lung adenocarcinoma. Overall, the EEF1D knockout in this genetic background provides a powerful tool for dissecting the interplay between translational control and oncogenic signaling.
Researchers can employ this knockout population in functional genomics and proteomics studies to identify EEF1D-dependent translation targets and to validate the eEF1 complex as a therapeutic vulnerability in NSCLC. Representative experimental approaches include western blotting for EEF1D and associated proteins, puromycin incorporation assays to measure translational output, cell viability and apoptosis assays in the presence of EGFR inhibitors, polysome profiling to assess ribosome occupancy, and RNA-sequencing to capture transcriptome-wide changes. For further information or customized gene-editing services, please contact Ascent Research.
